NEW YORK, May 16, 2017 /PRNewswire/ --
Stock-Callers.com presents four Health Care Plans companies for assessmenttoday: CVS Health Corp. (NYSE: CVS), Express Scripts Holding Co. (NASDAQ: ESRX), Aetna Inc. (NYSE: AET), and Cigna Corp. (NYSE: CI). These stocks are part of the Healthcare sector, which has received an "Outperform" rating from Charles
On Monday, shares in Woonsocket, Rhode Island headquartered CVS Health Corp. rose 0.32%, ending the day at $80.47. The stock recorded a trading volume of 3.79 million shares. The Company's shares have advanced 3.88% in the last one month, 2.91% over the previous three months, and 3.25% since the start of this year. The stock is trading above its 50-day moving average by 1.52%. Moreover, shares of CVS Health, which together with its subsidiaries, provides integrated pharmacy health care services, have a Relative Strength Index (RSI) of 51.30.
On April 28th, 2017, research firm Tigress Financial initiated a 'Buy' rating on the Company's stock.
On May 12th, 2017, CVS Health announced that Larry Merlo, the Company's President and CEO, will be speaking to investors at the UBS Global Healthcare Conference on May 24th, 2017 at approximately 10:00 a.m. ET. An audio webcast of the event will be broadcast simultaneously under the Investor Relations portion of the Company's website. CVS complete research report is just a click away and free at:
Shares in Saint Louis, Missouri headquartered Express Scripts Holding Co. ended the day 1.16% higher at $60.32 with a total trading volume of 4.34 million shares. The stock is trading below its 50-day moving average by 6.99%. Shares of the Company, which operates as a pharmacy benefit management company in the US, Canada, and Europe, have an RSI of 36.63.
On April 26th, 2017, research firm Edward Jones downgraded the Company's stock rating from 'Buy' to 'Hold'.
On May 08th, 2017, Express Scripts announced that it will present at the Bank of America Merrill Lynch 2017 Health Care Conference on Tuesday, May 16th, 2017, at 2:20 p.m. ET. The presentation will be broadcast via the Internet and can be accessed under the Investor Relations section of the Company's website. The complimentary report on ESRX can be downloaded at:
At the close of trading on Monday, shares in Hartford, Connecticut-based Aetna Inc. finished 0.48% lower at $142.21. A total volume of 4.29 million shares was traded, which was above their three months average volume of 2.64 million shares. The stock has advanced 10.56% in the last one month, 16.97% over the previous three months, and 15.36% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 7.69% and 16.23%, respectively. Additionally, shares of Aetna, which operates as a health care benefits company in the US, has an RSI of 70.10.
On May 09th, 2017, Aetna announced that Chairman and CEO, Mark T. Bertolini, is scheduled to present at the 2017 UBS Global Healthcare Conference in New York City on Monday, May 22nd, 2017, at 10:30 a.m. ET. A live, audio webcast will be accessible on the Company's Investor Relations website. Sign up for your complimentary research report on AET at:
Bloomfield, Connecticut headquartered Cigna Corp.'s shares recorded a trading volume of 1.58 million shares at the end of yesterday's session, which was higher than their three months average volume of 1.31 million shares. The stock closed the day 0.04% higher at $162.10. The Company's shares have advanced 7.77% in the past month, 11.17% in the previous three months, and 21.56% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.72% and 16.42%, respectively. Additionally, shares of Cigna, which provides insurance and related products and services in the US and internationally, have an RSI of 66.22.
On May 08th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $172 a share to $177 a share.
On May 12th, 2017, Cigna announced that the merger agreement with Anthem has been terminated. Anthem did not appeal the Delaware Court of Chancery's decision denying the former's motion for a preliminary injunction that sought to prevent Cigna from terminating the merger agreement. Cigna seeks prompt payment of the $1.85 billion reverse termination fee, and will pursue its claims for additional damages of over $13 billion against Anthem for the harm that it caused the Company and its shareholders. Get free access to your research report on CI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Adult immunization is needed for adults whose mandatory childhood vaccines were either missed out ...
Snake antivenom is a medicine used for the treatment of patients suffering from snake envenomation.
Breast Cancer Risk Assessment Calculator predicts the risk for breast cancer. Find list of breast ...View All